27867086|t|Diazoxide prevents reactive oxygen species and mitochondrial damage, leading to anti-hypertrophic effects
27867086|a|Pathological cardiac hypertrophy is characterized by wall thickening or chamber enlargement of the heart in response to pressure or volume overload, respectively. This condition will, initially, improve the organ contractile function, but if sustained will render dysfunctional mitochondria and oxidative stress. Mitochondrial ATP-sensitive K(+) channels (mitoKATP) modulate the redox status of the cell and protect against several cardiac insults. Here, we tested the hypothesis that mitoKATP opening (using diazoxide) will avoid isoproterenol - induced cardiac hypertrophy in vivo by decreasing reactive oxygen species (ROS) production and mitochondrial Ca(2+) - induced swelling. To induce cardiac hypertrophy, Swiss mice were treated intraperitoneally with isoproterenol (30 mg/kg/ day) for 8 days. Diazoxide (5 mg/kg/ day) was used to open mitoKATP and 5-hydroxydecanoate (5 mg/kg/ day) was administrated as a mitoKATP blocker. Isoproterenol - treated mice had elevated heart weight / tibia length ratios and increased myocyte cross-sectional areas. Additionally, hypertrophic hearts produced higher levels of H2O2 and had lower glutathione peroxidase activity. In contrast, mitoKATP opening with diazoxide blocked all isoproterenol effects in a manner reversed by 5-hydroxydecanoate. Isolated mitochondria from Isoproterenol - induced hypertrophic hearts had increased susceptibility to Ca(2+) - induced swelling secondary to mitochondrial permeability transition pore opening. MitokATP opening was accompanied by lower Ca(2+) - induced mitochondrial swelling, an effect blocked by 5-hydroxydecanoate. Our results suggest that mitoKATP opening negatively regulates cardiac hypertrophy by avoiding oxidative impairment and mitochondrial damage.
27867086	0	9	Diazoxide	T103	UMLS:C0012022
27867086	19	42	reactive oxygen species	T103	UMLS:C0162772
27867086	47	67	mitochondrial damage	T038	UMLS:C1096176
27867086	80	105	anti-hypertrophic effects	T033	UMLS:C0243095
27867086	119	138	cardiac hypertrophy	T038	UMLS:C1383860
27867086	159	163	wall	T017	UMLS:C0446987
27867086	164	174	thickening	T033	UMLS:C0205400
27867086	178	185	chamber	T017	UMLS:C0729936
27867086	186	197	enlargement	T038	UMLS:C0020564
27867086	205	210	heart	T017	UMLS:C0018787
27867086	301	308	improve	T033	UMLS:C0184511
27867086	313	318	organ	T017	UMLS:C0178784
27867086	319	339	contractile function	T038	UMLS:C1258017
27867086	384	396	mitochondria	T017	UMLS:C0026237
27867086	401	417	oxidative stress	T038	UMLS:C0242606
27867086	419	460	Mitochondrial ATP-sensitive K(+) channels	T103	UMLS:C0764439
27867086	462	470	mitoKATP	T103	UMLS:C0764439
27867086	472	480	modulate	T082	UMLS:C0443264
27867086	485	497	redox status	T038	UMLS:C0030012
27867086	505	509	cell	T017	UMLS:C0007634
27867086	538	545	cardiac	T017	UMLS:C0018787
27867086	591	599	mitoKATP	T103	UMLS:C0764439
27867086	600	607	opening	T082	UMLS:C1882151
27867086	615	624	diazoxide	T103	UMLS:C0012022
27867086	637	650	isoproterenol	T103	UMLS:C0022245
27867086	661	680	cardiac hypertrophy	T038	UMLS:C1383860
27867086	681	688	in vivo	T082	UMLS:C1515655
27867086	703	726	reactive oxygen species	T103	UMLS:C0162772
27867086	727	731	(ROS	T103	UMLS:C0162772
27867086	748	761	mitochondrial	T017	UMLS:C0026237
27867086	762	768	Ca(2+)	T103	UMLS:C0596235
27867086	779	787	swelling	T033	UMLS:C0038999
27867086	799	818	cardiac hypertrophy	T038	UMLS:C1383860
27867086	820	830	Swiss mice	T204	UMLS:C0162416
27867086	844	861	intraperitoneally	T082	UMLS:C0442120
27867086	867	880	isoproterenol	T103	UMLS:C0022245
27867086	909	918	Diazoxide	T103	UMLS:C0012022
27867086	951	959	mitoKATP	T103	UMLS:C0764439
27867086	964	982	5-hydroxydecanoate	T103	UMLS:C0098450
27867086	1021	1029	mitoKATP	T103	UMLS:C0764439
27867086	1039	1052	Isoproterenol	T103	UMLS:C0022245
27867086	1063	1067	mice	T204	UMLS:C0025929
27867086	1081	1086	heart	T017	UMLS:C0018787
27867086	1096	1101	tibia	T017	UMLS:C1279118
27867086	1130	1137	myocyte	T017	UMLS:C0225828
27867086	1138	1159	cross-sectional areas	T033	UMLS:C0243095
27867086	1188	1194	hearts	T017	UMLS:C0018787
27867086	1221	1225	H2O2	T103	UMLS:C0020281
27867086	1240	1271	glutathione peroxidase activity	T038	UMLS:C1151528
27867086	1286	1294	mitoKATP	T103	UMLS:C0764439
27867086	1295	1302	opening	T082	UMLS:C1882151
27867086	1308	1317	diazoxide	T103	UMLS:C0012022
27867086	1330	1343	isoproterenol	T103	UMLS:C0022245
27867086	1376	1394	5-hydroxydecanoate	T103	UMLS:C0098450
27867086	1405	1417	mitochondria	T017	UMLS:C0026237
27867086	1423	1436	Isoproterenol	T103	UMLS:C0022245
27867086	1460	1466	hearts	T017	UMLS:C0018787
27867086	1499	1505	Ca(2+)	T103	UMLS:C0596235
27867086	1516	1524	swelling	T033	UMLS:C0038999
27867086	1538	1580	mitochondrial permeability transition pore	T103	UMLS:C0908146
27867086	1581	1588	opening	T082	UMLS:C1882151
27867086	1590	1598	MitokATP	T103	UMLS:C0764439
27867086	1599	1606	opening	T082	UMLS:C1882151
27867086	1632	1638	Ca(2+)	T103	UMLS:C0596235
27867086	1649	1671	mitochondrial swelling	T038	UMLS:C0026244
27867086	1694	1712	5-hydroxydecanoate	T103	UMLS:C0098450
27867086	1739	1747	mitoKATP	T103	UMLS:C0764439
27867086	1748	1755	opening	T082	UMLS:C1882151
27867086	1756	1766	negatively	T033	UMLS:C0205160
27867086	1767	1776	regulates	T038	UMLS:C1327622
27867086	1777	1796	cardiac hypertrophy	T038	UMLS:C1383860
27867086	1834	1854	mitochondrial damage	T038	UMLS:C1096176